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OBJECTIVE — Although suboptimal glycemic control is known to be common in diabetic
adults, few studies have evaluated factors at the level of the physician-patient encounter. Our
objective was to identify novel visit-based factors associated with intensiﬁcation of oral diabetes
medications in diabetic adults.
RESEARCH DESIGN AND METHODS — We conducted a nonconcurrent prospective
cohort study of 121 patients with type 2 diabetes and hyperglycemia (A1C 8%) enrolled in an
academically afﬁliated managed-care program. Over a 24-month interval (1999–2001), we
identiﬁed 574 hyperglycemic visits. We measured treatment intensiﬁcation and factors associ-
ated with intensiﬁcation at each visit.
RESULTS — Provider-patient dyads intensiﬁed oral diabetes treatment in only 128 (22%) of
574 hyperglycemic visits. As expected, worse glycemia was an important predictor of intensiﬁ-
cation. Treatment was more likely to be intensiﬁed for patients with visits that were “routine”
(odds ratio [OR] 2.55 [95% CI 1.49–4.38]), for patients taking two or more oral diabetes drugs
(2.82 [1.74–4.56]), or for patients with longer intervals between visits (OR per 30 days 1.05
[1.00–1.10]).Incontrast,patientswithlessrecentA1Cmeasurements(OR30daysbeforethe
visit 0.53 [0.34–0.85]), patients with a higher number of prior visits (OR per prior visit 0.94
[0.88–1.00]), and African American patients (0.59 [0.35–1.00]) were less likely to have treat-
ment intensiﬁed.
CONCLUSIONS — Failure to intensify oral diabetes treatment is common in diabetes care.
Quality improvement measures in type 2 diabetes should focus on overcoming inertia, improv-
ing continuity of care, and reducing racial disparities.
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A
lthough glycemic control reduces
microvascular complications and
may reduce macrovascular compli-
cations (1–3), diabetic patients com-
monly have inadequately controlled
blood glucose (4–8). Recent evidence
suggests that lack of intensiﬁcation of di-
abetes medications in a timely fashion is a
powerful explanatory factor (4–6,9–11).
This decision to intensify treatment may
be affected by several factors, such as pa-
tient adherence (12) and preference,
competingmedicaldemands(13),orpro-
vider attitudes and knowledge (14).
Identifying barriers and promoters of
treatment intensiﬁcation is a crucial ﬁrst
step toward developing strategies to im-
prove blood glucose control in diabetic
adults. Although many studies have doc-
umented lack of adequate glycemic con-
trol (4–8) and failures to intensify
medications in subjects with diabetes (4–
6,9–11), few studies have evaluated fac-
tors associated with treatment
intensiﬁcation besides glycemic control
(13,15,16). Of these studies, two evalu-
ated a variety of visit-based factors associ-
ated with intensiﬁcation, but these had
limited generalizability (13,15) and did
not adjust for key confounders such as
patient adherence (13). No study has fo-
cused in detail on a variety of visit-based
factorsinadditiontopatientandprovider
factors that might inﬂuence oral diabetes
treatment intensiﬁcation.
Therefore, we conducted a noncon-
current prospective cohort study to iden-
tify novel barriers and promoters of
intensiﬁcation of oral diabetes medica-
tions in type 2 diabetic adults. We felt
these visit-based factors may be more
modiﬁable than durable patient and phy-
sician factors such as age or sex.
RESEARCH DESIGN AND
METHODS— We studied a cohort of
federal employees and their dependents
with type 2 diabetes who received pri-
mary care at any of 16 sites of an academ-
ically afﬁliated managed-care program in
Maryland. Individuals were classiﬁed as
having diabetes if 1) claims data showed
ICD-9 codes 250.xx, 357.2, 362.0,
366.41, or 648.0 or 2) electronic phar-
macy data indicated that insulin or oral
diabetes medications had been pre-
scribed.Eligiblesubjectshadmadetwoor
more primary care visits or one emer-
gency room visit or had a hospital stay
during the 24-month interval from 1 Jan-
uary 1999 to 31 December 2001. From
thispopulationof1,120diabeticpatients,
411 patients were chosen by systematic
random sampling using criteria based on
the Health Plan Employer Data and Infor-
mation Set sampling strategy. Of the 411,
we focused on the 122 patients receiving
oral diabetes medications and not on in-
sulin at study start. Electronic pharmacy
data were not available for 21 (5.1%) of
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and approved by the Johns Hopkins
School of Public Health Institutional Re-
view Board.
From 1 July 1999 to 31 December
2001, these 122 patients with diabetes
made 1,270 primary care visits. We ex-
cluded one patient and 142 visits for
which blood glucose control was uncer-
tainand18visitsforwhichintensiﬁcation
status was uncertain. At 574 of the re-
maining 1,110 visits (in 121 unique pa-
tients who saw 55 primary care
providers), glycemic control was poor
enough (i.e., A1C 8%) to warrant treat-
ment intensiﬁcation. The A1C threshold
of 8% for physician action is consistent
with practice guidelines developed by the
American Diabetes Association (17).
Data collection
Data were collected from two main
sources. From electronic ﬁles, we ab-
stracted data on enrollment, utilization,
laboratory results, and pharmacy use.
From written medical records, two
trainedregisterednursesusedastandard-
ized instrument to abstract data on med-
ical history and visit-based clinical
factors. A physician independently re-
viewed 98 (24%) of the 407 patient
charts, with good agreement ( 0.8) for
all objective measurements, including
A1C. We grouped these data into three
categories: 1) patient-related factors, 2)
provider-related factors, and 3) visit-
related factors.
Patient-related factors. From medical
records,weabstracteddataonweightand
height and cardiovascular comorbid con-
ditions. From enrollment databases, we
obtained age, sex, and race. Using the
electronic pharmacy database, we calcu-
lated patient adherence according to an
algorithm with number of pills and days
supply developed by Steiner et al. (18). A
score of 1.0 corresponds to 100% adher-
ence and a score of 0.50 to 50% adher-
ence. The score can exceed 1.0 (100%) if
a patient reﬁlls a prescription early. From
claims data, we determined comorbidity,
using ICD-9 codes and patient demo-
graphics to create resource utilization
bands (RUBs) (19). A higher RUB indi-
cated higher patient comorbidity.
Provider-related factors. Using data
frompublicwebsitespostedbytheMary-
land Board of Physicians and American
Medical Association, we determined pro-
vider sex and graduation year (20,21).
Visit-related factors. From the labora-
tory database, we abstracted A1C, serum
glucose, LDL cholesterol, and creatinine.
WeabstractedthemostrecentA1Cbefore
the index visit. From medical records, for
each visit we abstracted data on prescrip-
tion side effects; provider counseling re-
garding diet, exercise, medication
adherence, glucose control, or smoking
cessation; visit type (routine versus ur-
gent); specialty referrals; and inﬂuenza
and/or pneumonia vaccination.
We used the electronic appointment
database to determine other visit-related
factors including missed appointments,
the interval between visits, and the num-
ber of appointments as well as whether
the patient saw his or her regular primary
careproviderornot.Theregularprovider
was the provider seen most frequently by
the patient.
Intensiﬁcation of oral diabetes
treatment
Using the electronic pharmacy database,
we deﬁned “intensiﬁcation” as either 1)
ﬁlling a prescription for a new oral diabe-
tes medication or 2) ﬁlling a prescription
for a higher dose of a previously pre-
scribed medication, without a corre-
sponding decline in dose of another oral
diabetes medication within 1 month of
the index visit (15).
Statistical analysis
We used generalized estimating equa-
tions with an exchangeable correlation
structure to construct unadjusted and
partially adjusted (for patient age, race,
sex,comorbidityusingtheRUBs,andgly-
cemic control using A1C) logistic regres-
sion models for each of these variables.
Because individual patients typically
made about seven visits during 24
months, all models accounted for patient
clustering. We used body weight strati-
ﬁed by sex as a marker of adiposity, be-
causeheightwasonlyavailablefor26%of
patients.
We then used a two-step approach to
develop the ﬁnal multivariable model.
First, we used our clinical judgment and
prior literature to choose factors for the
ﬁnal model. These variables included
having a routine visit, A1C, and patient
age, race, sex, and comorbidity as mea-
suredbyRUBs.A1Cwashandledasacat-
egorical variable because there was a
signiﬁcant change in slope at 9%. We
then constructed separate multivariable
models for patient, provider, and visit
characteristics.
In addition to variables included on
the basis of clinical judgment, we also in-
cluded in the ﬁnal model several of the
most statistically signiﬁcant variables
from each of the ﬁrst-step models (P 
0.05). Clinic site was not included in
these models because there were no sta-
tistically signiﬁcant differences between
clinic sites. Tests of signiﬁcance were
two-tailed, with an  level of 0.05.
Analyses were performed using Stata
(intercooled version 8.0; StataCorp,
College Station, TX).
RESULTS
Patient, visit, and provider
characteristics
Table 1 presents selected characteristics
of 121 patients and their 574 hyperglyce-
mic visits. Most were older white or Afri-
can American men. These federal
employees and their dependents were
highly adherent to their oral diabetes
medications. Approximately two-thirds
had hypertension, and approximately
one-quarter had coronary heart disease.
They averaged seven primary care visits
over 2 years. At baseline, approximately
half of the patients were taking one or
fewer oral diabetes medications.
The 55 primary care providers were
mostly internal medicine (41%) or family
practice (38%) physicians. Primary care
providers intensiﬁed oral diabetes medi-
cations at only 128 (22%) of 574 hyper-
glycemic visits. Sixty-seven (52%) of
these intensiﬁed prescriptions were ﬁlled
within 24 h of the patients’ appointment
with their primary care provider, 19
(15%) were ﬁlled between 2 days and 1
week,20(16%)wereﬁlledbetween1and
2 weeks, and the remaining 22 (17%)
wereﬁlledbetween2weeksand1month.
When we dropped visits with an out-of-
date A1C (3 months old), intensiﬁca-
tionratesincreasedto26%.Ifweusedthe
medical record to determine intensiﬁca-
tion, the intensiﬁcation rate rose to 32%.
Using the 574 index hyperglycemic
visits, the mean A1C was 9.5%. Most of
thevisitswereroutine(66%,n380vis-
its) appointments with regular providers
(53%,n303).Patientssawtheirregular
provider at 61% of routine visits.
Factors associated with treatment
intensiﬁcation
Patient factors. Table 2 shows associa-
tions between selected patient factors and
intensiﬁcation. Older age (odds ratio
[OR] per 10 years 1.42 [95% CI 1.08–
1.86]) and lower comorbidity (1.60
[1.00–2.57]) were moderately associated
Failure to intensify oral diabetes treatment
26 DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009with intensiﬁcation of diabetes medica-
tions in the partially adjusted model. In-
tensiﬁcation was 31% less likely in
African American compared with white
patients, reaching borderline statistical
signiﬁcance in the partially adjusted
model (P  0.08). Income, sex, and med-
ication adherence were not associated
with intensiﬁcation. Several other patient
factors known to increase the risk of ma-
crovascularormicrovasculardiseasewere
not associated with intensiﬁcation, in-
cluding weight, alcohol use, smoking sta-
tus, speciﬁc individual comorbidity such
as coronary artery disease, 2-year mean
LDL cholesterol and creatinine, and fam-
ily history of heart disease (all P  0.05;
data not shown).
Primary care provider factors. No pro-
vider factors (including provider type,
year of graduation from medical school,
and sex) were signiﬁcantly related to in-
tensiﬁcation of diabetes medications (all
P  0.05; data not shown).
Visit-related factors. Table 2 also shows
associations between selected visit-
related factors and intensiﬁcation. Pro-
vider-patient dyads were about twice as
likely to intensify treatment when the pa-
tients had moderate to severe hyperglyce-
mia(A1C9.0%)comparedwithmildto
moderate hyperglycemia (A1C between
8.0 and 9.0%) (supplemental Fig. 1
[available in an online appendix at http://
dx.doi.org/10.2337/dc08-1297]). Mean
A1C values at the previous and current
hyperglycemicvisitswerelessstronglyas-
sociated with intensiﬁcation at the cur-
rent visit (OR 2.31) than the A1C value
from the current visit alone (1.83).
Other positive associations with the
decision to intensify treatment included
having a routine visit, taking more than
one oral diabetes medication at the visit,
receiving counseling on glucose control,
having missed an appointment, or having
a longer interval between visits. In con-
trast, provider-patient dyads were less
likely to intensify oral diabetes medica-
tions if the A1C was measured 30 days
beforethevisitandifthepatienthadmore
priorvisits.Othervisitfactorsincluding
intensiﬁcation at the prior hyperglyce-
mic visit, diet and medication adher-
ence counseling, referral to a diabetes-
related specialist, and seeing one’s
regular provider were not associated
with intensiﬁcation.
Final multivariable model
Many of the associations identiﬁed in the
partially adjusted models persisted in the
Table 1—Selected characteristics of 121 patients with diabetes, their 55 primary care pro-
viders, and their 574 visits with suboptimally controlled glycemia
Patient characteristics
n 121
Age (years) 61  8
Age categories (%)
40–49 years 9
50–59 years 36
60–69 years 41
70 years 14
Sex (%)
Male 61
Female 39
Race (%)
White 55
African American 33
Other or missing 12
Body weight (lb)
Men 226  38
Women 191  36
Adherence score* 1.02  0.23
Current or ex-smoker (%)† 20
Current or ex-alcohol use (%)† 14
Comorbid conditions/complications (%)
Coronary heart disease 21
Stroke/transient ischemic attack 8
Hyperlipidemia 55
Hypertension 66
Retinopathy 3
Neuropathy 5
Nephropathy 6
Peripheral vascular disease 8
Taking 1 oral diabetes medications (%) 54
Primary care provider characteristics
n 55
Year of graduation from medical school 1,985  9
Provider sex (%)
Male 51
Female 42
Missing 7
Provider specialty (%)
Internal medicine 41
Family practice 38
Physician assistant, nurse practitioner, or resident 15
Missing 6
Visit characteristics
n 574
A1C (absolute percentage points) 9.5  1.5
Random serum glucose (mg/dl) 215  104
Hyperglycemic visits to the primary care provider (over
24 months)
5  3
Visit type (%)
Routine visit 66
Urgent visit 34
1 oral diabetes medication at time of visit (%) 45
Interval since the last visit (days)‡ 52 (22–119)
Prescription side effects noted in the chart (%) 6
Patient counseled on diet (%) 25
Patient counseled on smoking (%) 2
Patient counseled on medication adherence (%) 12
Continued on facing page
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was the only patient factor that was mar-
ginally associated (P  0.05) with inten-
siﬁcation: provider-patient dyads
appeared 41% less likely to intensify dia-
betes medications in African American
patients compared with white patients,
after adjustment for key confounders.
Visit-related factors independently asso-
ciated with treatment intensiﬁcation were
higherA1C,havingaroutinevisit,having
A1C measured within 30 days before the
visit, having fewer prior visits, having a
longer interval between visits, and taking
morethanoneoraldiabetesmedicationat
the time of the visit. No provider charac-
teristics were independently associated
with intensiﬁcation (data not shown);
however,interprovidervariancewas19%
when assessed in a multilevel model.
When we drop the 171 visits at which
A1C was out of date (3 months old),
similar point estimates are seen, although
some variables lose statistical signiﬁcance
because of lack of power.
CONCLUSIONS — Inthishighlyad-
herent cohort of hyperglycemic adults
with diabetes, failure to intensify treat-
ment for diabetes was a common prob-
lem: primary care provider-patient dyads
intensiﬁed treatment at only 22% of visits
when blood glucose was elevated. Several
visit-related factors and one potential pa-
tient-related factor appeared to inﬂuence
the decision to intensify treatment. Pro-
vider-patient dyads were more likely to
intensifytreatmentatroutinevisitsandin
patients with worse hyperglycemia, tak-
ing more oral diabetes medications, hav-
ing fewer prior visits, or having longer
intervals between visits but seemed less
likely to intensify treatment in African
American patients compared with white
patients.
The main strength of our study was
the availability of detail at the level of the
individual clinic visit, made possible by
standardized data abstraction from
medicalrecordslinkedtoavailableelec-
tronic databases. Unlike most previous
studies, this level of detail allowed us to
investigate speciﬁc, modiﬁable visit-
based factors.
Nonetheless, several limitations
should be considered when these results
are interpreted. First, because we used
pharmacy records to identify intensiﬁca-
tion, we probably missed some episodes
whentheproviderrecommendedintensi-
ﬁcation but the patient declined or signif-
icantly delayed ﬁlling the prescription.
Although our patient population was
otherwise highly adherent, the intensi-
ﬁcation rate of 22% that we observed
was slightly lower than rates in other
studies (ranging from 32 to 57%)
(10,12,13,15,16). The lower-than-
expected intensiﬁcation rate may be due
to several factors: 1) delay by patients in
ﬁllingaprescriptionby1month,2)dif-
ferences in study design (i.e., length of
time allowed for intensiﬁcation such as 3
months–1 year after a visit) (12,16),
and/or 3) study population differences
(10).
Second, our data were collected from
1999 to 2001 and may not be fully gen-
eralizable to the present day. Systems
changes such as electronic medical
records and increased awareness of clini-
cal inertia, for instance, might alter inten-
siﬁcation rates yet would be unlikely to
affectthefactorswefoundassociatedwith
intensiﬁcation such as glycemic control
andtimesincelastmeasuredA1C.Infact,
physicianratesofintensiﬁcationwerestill
low (33–43%) in two recently conducted
studies (12,13). Also, our choice of pa-
tients from a single managed-care pro-
vider enhanced convenience at the
possible expense of generalizability.
However, our study sample was racially
diverse and included men and women
who saw multiple providers at 16 differ-
ent clinic sites.
Third, many of the visit-based factors
were based on medical record review. Al-
though we attempted to evaluate all clin-
ical variables at the visit that could affect
intensiﬁcation,wewereunabletocapture
everything. If a physician did not record
anything related to prescription side ef-
fectsinthemedicalrecord,thenwecoded
this as no side effects. Also, the regular
providerwasdeﬁnedastheprovidermost
frequently visited. This assumption may
have led to an underestimation of regular
provider visits if a patient switched pro-
viders. This potential for misclassiﬁcation
along with the low rate of intensiﬁcation
may have biased some of these items to-
wardthenullofnosigniﬁcanteffects(i.e.,
type II error).
Fourth, we were unable to assess vis-
its to endocrinologists, so we were unable
todeterminetheeffectsofcomanagement
on intensiﬁcation. However, this type of
comanagement appears to be uncommon
inoursample,becausewecouldﬁndonly
twonewreferralstoendocrinologistsdur-
ing the 2-year interval. Finally, we were
unable to assess some relevant provider
andpatientcharacteristicssuchasknowl-
edge, beliefs, and attitudes about diabetes
therapy.
Since 1980, at least two studies have
evaluatedspeciﬁcvisit-basedfactorsasso-
ciated with intensiﬁcation of diabetes
medications (13,15). Both showed that
worse glycemic control was associated
with treatment intensiﬁcation (13,15).
Berlowitz et al. (15) reported several pos-
itive associations with intensiﬁcation of
diabetes medications, including longer
intervals between visits, A1C being ob-
tained within the last 3 months, patients
taking insulin, and patients having re-
ceived supplies for self-monitoring of
blood glucose. Parchman et al. (13) re-
ported an inverse association between an
increasednumberofpatientconcernsand
intensiﬁcation.Theresultsfromthesetwo
studies are generally consistent with our
ﬁndings. We also found higher intensiﬁ-
cation with worse glycemic control, more
recentA1Cmeasurements,andlongerin-
tervals between visits.
In contrast with previous studies, we
had access to more data at the level of the
individual visit. These data yielded sev-
eral novel observations. Provider-patient
dyadsweremorelikelytointensifydiabe-
tes treatment at a routine visit and in pa-
tients with fewer prior visits but may be
less likely to intensify treatment for Afri-
Table 1—Continued
Patient counseled on glucose control (%) 13
Primary care provider type (%)
Internal medicine 58
Family practice 32
Physician assistant, nurse practitioner, or resident 8
Missing 2
Patients seen by the regular provider at the visit (%) 53
Data are means  SD, %, or median (interquartile range). Suboptimally controlled glycemia was deﬁned as
anA1C8%.*Meanadherencescoreof1.0meansthatthesubjectwas100%adherent.Subjectscouldhave
100%adherenceiftheyreﬁlledtheirprescriptionearly.†Currentorex-smokerdeﬁnedashavingsmoking
use listed on the problem list in the medical record. Current or ex-alcohol use deﬁned as having alcohol use
listed on the problem list in the medical record.
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glycemia
Factors Intensiﬁcation
No
intensiﬁcation
Univariate
model*
Partially adjusted
model*
n 128 446
Patient-related factors
Age (per 10 years) 1.18 (0.91–1.53) 1.42 (1.08–1.86)
Sex
Male 72 (56) 246 (55) — —
Female 56 (44) 200 (45) 0.96 (0.64–1.44) 0.84 (0.57–1.23)
Race
White 71 (56) 226 (51) — —
African American 40 (31) 174 (39) 0.73 (0.47–1.14) 0.69 (0.46–1.05)
Other/unknown 17 (13) 46 (10) 1.17 (0.63–2.19) 1.30 (0.70–2.40)
RUBs
Low 47 (37) 118 (26) 1.61 (1.02–2.54) 1.60 (1.00–2.57)
Medium 47 (37) 186 (42) — —
High 34 (26) 142 (32) 0.95 (0.59–1.54) 0.88 (0.55–1.42)
Annual household income (USD)
40,000 33 (26) 117 (26) — —
40,000–65,000 66 (52) 205 (46) 1.13 (0.70–1.84) 0.95 (0.57–1.61)
65,000 28 (22) 121 (27) 0.81 (0.46–1.45) 0.78 (0.42–1.43)
Unknown 1 (1) 3 (1) — —
Adherence score
0.80 23 (16) 72 (18) — —
0.80 104 (82) 367 (81) 0.89 (0.53–1.52) 0.92 (0.55–1.55)
Unknown 1 (2) 7 (1) 0.44 (0.05–3.95) 0.37 (0.05–2.88)
Visit-related factors
Number of oral diabetes medications
2 medications 39 (30) 218 (49) — —
2 medications 89 (70) 228 (51) 2.27 (1.47–3.48) 2.18 (1.42–3.35)
Visit type
Urgent 21 (16) 173 (39) — —
Routine 107 (84) 273 (61) 3.24 (1.96–5.38) 2.90 (1.72–4.90)
Regular provider seen at visit
No 58 (45) 213 (48) — —
Yes 70 (55) 233 (52) 1.12 (0.75–1.67) 1.12 (0.75–1.66)
Counseled patient on diet
No 86 (67) 342 (77) — —
Yes 42 (33) 104 (23) 1.60 (1.04–2.46) 1.54 (0.99–2.41)
Counseled patient on medication adherence
No 110 (86) 394 (88) — —
Yes 18 (14) 52 (12) 1.24 (0.69–2.20) 1.10 (0.61–2.00)
Counseled patient on glucose control
No 103 (80) 396 (89) — —
Yes 25 (20) 50 (11) 1.93 (1.14–3.27) 1.79 (1.03–3.09)
Nonadherent between visits
No 108 (84) 404 (91) — —
Yes 20 (16) 42 (9) 1.78 (1.00–3.16) 1.87 (1.01–3.45)
Referred to diabetes-related specialist at visit†
No 100 (78) 383 (86) — —
Yes 28 (22) 63 (14) 1.70 (1.03–2.79) 1.65 (0.98–2.76)
Random serum glucose
200 mg/dl 47 (37) 212 (48) — —
200 mg/dl 69 (54) 181 (41) 1.71 (1.12–2.62) 1.42 (0.89–2.27)
Unknown 12 (9) 53 (12) 1.01 (0.50–2.06) 1.38 (0.66–2.86)
A1C
9%‡ 42 (33) 236 (53) — —
9%‡ 86 (67) 210 (47) 2.31 (1.52–3.51) 2.44 (1.60–3.74)
Continued on facing page
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tients. To our knowledge, no one has
evaluated the effects of continuity of care
on intensiﬁcation of diabetes medica-
tions. Routine visits appear to allow pro-
viders to focus on chronic illnesses such
asdiabetesoverotherissues.Thetwopre-
vious visit-based studies were unable to
evaluate African American race because
their patient populations were mainly
white and Hispanic, respectively. Two
other studies with fewer visit-level data
showed conﬂicting results with regard to
race. Grant et al. (12) reported a nonsig-
niﬁcant16%decreasedriskofintensiﬁca-
tion, and Rodondi et al. (16) reported a
statistically signiﬁcant decreased propor-
tionofintensiﬁcation,althoughtheywere
unabletoadjustforkeyconfounderssuch
as patient adherence. To our knowledge,
ours is the ﬁrst study to evaluate race in
addition to other modiﬁable visit-based
factors and key confounders such as pa-
tient adherence. However, it is difﬁcult to
fully adjust for socioeconomic issues and
patient adherence. For instance, if delays
in ﬁlling prescriptions or decisions not to
ﬁll a prescription vary by race, then the
racial disparity may be due to differences
in patient adherence not captured by our
method of accounting for patient adher-
ence based strictly on prescription ﬁlling
patterns. The 38% decreased odds of in-
tensiﬁcationinAfricanAmericansisespe-
ciallydisturbinggiventhehigherdiabetes
diseaseburdeninAfricanAmericans(22–
24). Last, having more prior visits was in-
versely associated with intensiﬁcation.
Thisﬁndingmaybeexplainedbycompet-
ing demands. The patient with more fre-
quent visits may be dealing with other
issues besides hyperglycemia. In fact, we
found signiﬁcantly more intensiﬁcation
after longer intervals between visits.
Four studies may have evaluated the
associationofotherpatientcharacteristics
with intensiﬁcation and showed mixed
results(12,13,15,16).Grantetal.(12)fo-
cused on evaluating the relationship be-
tweenbaselinepatientadherencetoinitial
diabetes medications and subsequent in-
tensiﬁcation in the face of hyperglycemia
over the next year and found higher in-
Table3—Factorsindependentlyassociatedwithintensiﬁcationoforaldiabetesmedicationsat
562 visits with suboptimally controlled glycemia
Characteristics (n  562 visits
for 119 patients)*
Adjusted OR
(95% CI)* P value
Patient factors
Age (per 10 years) 1.29 (0.94–1.78) 0.11
Male sex (vs. female) 0.98 (0.62–1.55) 0.93
Race
African American (vs. white) 0.59 (0.35–1.00) 0.05
Other (vs. white) 1.17 (0.57–2.37) 0.67
Comorbidity measure (RUB)
Low comorbidity (vs. medium) 1.17 (0.68–2.02) 0.56
High comorbidity (vs. medium) 0.95 (0.56–1.62) 0.85
Income (per $1,000) 0.99 (0.98–1.01) 0.42
Adherence score (80% vs. 80% adherent) 0.89 (0.49–1.60) 0.69
Visit factors
A1C (9% vs. 9%) 2.24 (1.40–3.58) 0.001
Time since last A1C (30 vs. 30 days)† 0.53 (0.34–0.85) 0.008
No. oral diabetes medications (2 vs. 2) 2.82 (1.74–4.56) 0.001
Routine visit (vs. urgent) 2.55 (1.49–4.38) 0.001
No. prior visits (per visit) 0.94 (0.88–1.00) 0.05
Interval between visits (per 30 days) 1.05 (1.00–1.10) 0.05
Suboptimally controlled glycemia was deﬁned as A1C 8%. *ORs have been adjusted for all other variables
in the model and take into account clustering by the patient. Because of missing data, only 562 of the 574
visits (119 of 121 patients) have been analyzed in the ﬁnal model. †Results change only minimally when we
use time since last A1C as a continuous variable as opposed to a categorical variable.
Table 2—Continued
Factors Intensiﬁcation
No
intensiﬁcation
Univariate
model*
Partially adjusted
model*
Time since last A1C
30 days 79 (62) 183 (41) — —
30 days 49 (38) 263 (59) 0.43 (0.29–0.64) 0.45 (0.30–0.68)
Time since last visit
30 days 34 (27) 141 (31) — —
31–90 days 36 (28) 164 (37) 0.90 (0.54–1.51) 0.91 (0.53–1.56)
90 days 46 (36) 120 (27) 1.57 (0.95–2.61) 1.53 (0.90–2.60)
First visit 12 (9) 21 (5) 2.34 (1.05–5.22) 1.96 (0.84–1.56)
Number of prior visits (per visit) 0.93 (0.88–0.98) 0.95 (0.90–1.00)
Intensiﬁcation at prior visit§
No 63 (49) 292 (65) — —
Yes 22 (17) 82 (18) 1.45 (0.85–2.47) 1.30 (0.75–2.25)
First visit/unknown 43 (34) 72 (16) 2.98 (1.86–4.76) 2.88 (1.77–4.69)
Data are n (%) or OR (95% CI). Suboptimally controlled glycemia was deﬁned as A1C 8%. *The univariate model is a crude OR of intensiﬁcation of oral diabetes
medications, which takes into account clustering by patient. The partially adjusted model is the OR of intensiﬁcation of oral diabetes medications adjusting for age,
sex, race, and comorbidity using resource utilization bands and most recent A1C before the visit. †Referral to a diabetes-related specialist could include any of the
following: neurologist, podiatrist, nutritionist, ophthalmologist, nephrologist, or endocrinologist. ‡% equals absolute percentage points. §This variable is intensi-
ﬁcationatthepriorsuboptimallycontrolledvisit.Priorintensiﬁcationstatuswasunknownfortheﬁrstvisitandwashighlycorrelatedwiththenumberofpriorvisits
(r
2  0.4, P  0.001). Therefore, the number of prior visits was used in the ﬁnal model as the more representative variable.
Failure to intensify oral diabetes treatment
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tients. We did not ﬁnd an association
between intensiﬁcation and patient ad-
herence, but our ability to detect an asso-
ciation was probably limited by the
generallyhighadherencerateofourstudy
sample. Berlowitz et al. (15) did not re-
port ﬁnding any signiﬁcant patient factor,
but it is not clear which patient factors
they evaluated. Parchman et al. (13) also
reported no signiﬁcant associations be-
tween patient demographic factors and
intensiﬁcation of glycemic medications.
Rodondi et al. (16) reported a signiﬁcant
association between younger age, dyslip-
idemia, hypertension, and female sex and
intensiﬁcation of diabetes medications.
The absolute differences were small (5–
10% between groups), and these differ-
ences were not supported in the other
studies with smaller sample sizes. Con-
ﬂicting results may be due to differences
in adjustment, power to detect small dif-
ferences, and/or differences in patient
populations. We did not ﬁnd a signiﬁcant
association between age, sex, comorbidity,
and intensiﬁcation once we adjusted for
other important modiﬁable visit-based
factors such as having a routine visit.
No prior studies evaluated the associ-
ation of provider characteristics with in-
tensiﬁcation. However, a 1995 survey/
interview subject to self-report bias
assessed provider attitudes toward diabe-
tes care and reported several potential
barriers: lack of adequate time/resources,
hypoglycemiaconcerns,lackofhypergly-
cemic symptoms, and treatment frustra-
tion (14). Although we were unable to
evaluate provider attitude, knowledge, or
beliefs,wefoundnoassociationsbetween
provider demographics and type with in-
tensiﬁcation.Interprovidervarianceinin-
tensiﬁcation was 19% in a multilevel
model, and the speciﬁc components of this
variance will need further investigation.
In summary, failure to intensify oral
diabetes medications is a common prob-
lem in diabetes care. Failure is less likely
atroutinevisitsandinpatientswithworse
hyperglycemia, fewer prior visits, longer
intervals between visits, and use of more
oral diabetes medications. However, fail-
ure may be more likely for African Amer-
icans. Quality improvement measures in
type 2 diabetes should be focused on
overcominginertia,improvingcontinuity
of care, and reducing racial disparities.
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